RT Journal Article
T1 Metabolomic profile of cancer stem cell-derived exosomes from patients with malignant melanoma
A1 Palacios-Ferrer, José Luis
A1 García-Ortega, María Belén
A1 Gallardo-Gómez, María
A1 García, María Ángel
A1 Díaz, Caridad
A1 Boulaiz, Houria
A1 Valdivia, Javier
A1 Jurado, José Miguel
A1 Almazan-Fernandez, Francisco M.
A1 Arias-Santiago, Salvador
A1 Amezcua, Víctor
A1 Peinado, Héctor
A1 Vicente, Francisca
A1 Pérez Del Palacio, José
A1 Marchal, Juan A.
K1 Biomarkers
K1 Cancer stem cells
K1 Exosomes
K1 Malignant melanoma
K1 Metabolomics
K1 Biomarcadores
K1 Células madre neoplásicas
K1 Exosomas
K1 Melanoma
K1 Metabolómica
AB Malignant melanoma (MM) is the most aggressive and life-threatening form of skin cancer. It is characterized by an extraordinary metastasis capacity and chemotherapy resistance, mainly due to melanoma cancer stem cells (CSCs). To date, there are no suitable clinical diagnostic, prognostic or predictive biomarkers for this neoplasia. Therefore, there is an urgent need for new MM biomarkers that enable early diagnosis and effective disease monitoring. Exosomes represent a novel source of biomarkers since they can be easily isolated from different body fluids. In this work, a primary patient-derived MM cell line enriched in CSCs was characterized by assessing the expression of specific markers and their stem-like properties. Exosomes derived from CSCs and serums from patients with MM were characterized, and their metabolomic profile was analysed by high-resolution mass spectrometry (HRMS) following an untargeted approach and applying univariate and multivariate statistical analyses. The aim of this study was to search potential biomarkers for the diagnosis of this disease. Our results showed significant metabolomic differences in exosomes derived from MM CSCs compared with those from differentiated tumour cells and also in serum-derived exosomes from patients with MM compared to those from healthy controls. Interestingly, we identified similarities between structural lipids differentially expressed in CSC-derived exosomes and those derived from patients with MM such as the glycerophosphocholine PC 16:0/0:0. To our knowledge, this is the first metabolomic-based study aimed at characterizing exosomes derived from melanoma CSCs and patients' serum in order to identify potential biomarkers for MM diagnosis. We conclude that metabolomic characterization of CSC-derived exosomes sets an open door to the discovery of clinically useful biomarkers in this neoplasia.
PB John Wiley & Sons Ltd  on behalf of Federation of European Biochemical Societies
SN 1574-7891
YR 2020
FD 2020-11-25
LK http://hdl.handle.net/10668/4018
UL http://hdl.handle.net/10668/4018
LA en
NO Palacios-Ferrer JL, García-Ortega MB, Gallardo-Gómez M, García MÁ, Díaz C, Boulaiz H, et al. Metabolomic profile of cancer stem cell-derived exosomes from patients with malignant melanoma. Mol Oncol. 2021 Feb;15(2):407-428
DS RISalud
RD Apr 14, 2025